US and Japanese distributors for Raggio-Italgene:
This article was originally published in Clinica
Executive Summary
Italy-based Raggio-Italgene has appointed Oncor (US) and Medical & Biological Laboratories (Japan) as exclusive distributors of its C-Trak kits for lymphoma and leukaemia. Oncor's oncology marketing manager, David Parker, says the C-Trak DNA-probes complement its clinical and research products. MBL, which produces antibodies and antisera, immunoassays and reagents for autoantibodies and plasma proteins, says the agreement will enable it to enter the cancer field. In addition to its marketed C-Trak products for lymphoma, leukaemia and cystic fibrosis, Raggio is developing probes for prostate and breast cancer, ss-thalassaemia and several infectious diseases. The Italian company expects to appoint an exclusive distributor for Europe soon.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.